About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Multi-Center Study of ManNAc for GNE Myopathy | Clinical Trials | Clareo Health

Active Not RecruitingPhase 2

Multi-Center Study of ManNAc for GNE Myopathy

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy

NCT04231266•Leadiant Biosciences, Inc.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

GNE Myopathy

Interventions

ManNAc

Placebo

Locations

10

United States

Locations (10)

UCLA

Los Angeles, California, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas, Medical Center

Kansas City, Kansas, United States

NIH Clinical Center

Bethesda, Maryland, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

Key Dates

Start Date

April 5, 2022

Primary Completion Date

June 27, 2025

Completion Date

October 30, 2025

Last Updated

June 13, 2025

Related Studies

COMPLETEDPhase 3

Efficacy Confirmation Study of NPC-09

NCT04671472

GNE MyopathyDistal Myopathy With Rimmed Vacuoles (DMRV)+2 more

COMPLETEDPhase 3

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

NCT02377921

Hereditary Inclusion Body MyopathyDistal Myopathy With Rimmed Vacuoles+2 more

COMPLETEDPhase 2

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

NCT02346461

TERMINATEDPhase 2

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

NCT02731690

Hereditary Inclusion Body MyopathyDistal Myopathy With Rimmed Vacuoles+4 more

COMPLETEDPhase 1

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

NCT01634750

Hereditary Inclusion Body Myopathy (HIBM)GNE Myopathy

COMPLETEDPhase 2

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT01517880

GNE MyopathyHereditary Inclusion Body Myopathy

View all related studies

Sponsors

Lead Sponsor

Leadiant Biosciences, Inc.

Collaborators

Brigham and Women's Hospital
National Human Genome Research Institute (NHGRI)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH (NIAMS and NIND) as part of NeuroNext

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions